INAB IN8BIO INC

IN8bio to Present at the TD Cowen 45th Annual Health Care Conference

IN8bio to Present at the TD Cowen 45th Annual Health Care Conference

NEW YORK, Feb. 26, 2025 (GLOBE NEWSWIRE) -- . (Nasdaq: INAB), a leading clinical-stage biopharmaceutical company focused on innovative gamma-delta T cell therapies, today announced that William Ho, CEO and co-founder, will be presenting at the TD Cowen 45th  Annual Health Care Conference on Monday, March 3, 2025, at 10:30 a.m. ET.

A live webcast and replay will be available under "Events and Presentations" in the News & Presentations section of the IN8bio website at .

About IN8bio

IN8bio is a clinical-stage biopharmaceutical company developing gamma-delta T cell-based immunotherapies for cancer patients. Gamma-delta T cells are a specialized population of T cells that possess unique properties, including the ability to differentiate between healthy and diseased tissue. The company’s lead program INB-400 is in a Phase 2 trial in GBM. Additional programs include Phase 1 trials in solid and hematologic tumors, including INB-200 for GBM and INB-100 for patients with hematologic malignancies undergoing transplantation. For more information about IN8bio, visit .

Investor & Corporate Contact

Glenn Schulman, PharmD, MPH

IN8bio, Inc.

203.494.7411

Media Contact

Kimberly Ha

KKH Advisors

917.291.5744



EN
26/02/2025

Underlying

INABIN8BIO INC

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on IN8BIO INC

 PRESS RELEASE
Free
INAB IN8BIO INC

IN8bio Reports Third Quarter 2025 Financial Results and Recent Busines...

IN8bio Reports Third Quarter 2025 Financial Results and Recent Business Highlights Presented new preclinical data on INB-619, a novel gamma-delta (γδ) T cell engager (TCE), demonstrating equivalent potency comparable to FDA-approved commercial products with minimal adverse cytokine release, highlighting its potential to achieve deep B cell depletion with an improved safety profileExpanded Phase 1 INB-100 trial to The James Comprehensive Cancer Center at The Ohio State University, supporting faster enrollment to complete the Phase 1 expansion cohortContinued to advance IN8bio’s proprietary γ...

9h / 41m 1 EN
 PRESS RELEASE
Free
INAB IN8BIO INC

IN8bio Expands INB-100 Phase 1 Clinical Trial with Addition of The Ohi...

IN8bio Expands INB-100 Phase 1 Clinical Trial with Addition of The Ohio State University as New Site NEW YORK, Oct. 29, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: INAB), a clinical-stage biopharmaceutical company developing innovative gamma-delta T cell therapies for cancer and autoimmune diseases, today announced that The Ohio State University has been added as a new clinical site in the ongoing Phase 1 trial of the Company’s INB-100, a donor-derived allogeneic gamma-delta T cell therapy for patients with leukemias undergoing haploidentical stem cell transplantation. The addition of this leadin...

October 29, 2025 1 EN
 PRESS RELEASE
Free
INAB IN8BIO INC

IN8bio Presents T cell Engager Data Demonstrating Deep B Cell Depletio...

IN8bio Presents T cell Engager Data Demonstrating Deep B Cell Depletion for Autoimmune Indications INB-619 demonstrated equivalent efficacy to the FDA approved, commercial T Cell Engagers (TCE) compounds, blinatumomab and mosunetuzumab, with minimal adverse cytokine release, highlighting a targeted approach that potentially allows for safer deep B cell depletion.INB-619 is the first pan-gamma delta (γδ) T cell engager designed to significantly expand multiple γδ T cell subsets for efficient, durable target elimination.INB-619 achieved robust γδ T cell expansion and complete B cell depletion...

October 27, 2025 1 EN
 PRESS RELEASE
Free
INAB IN8BIO INC

IN8bio Reports Second Quarter 2025 Financial Results and Recent Busine...

IN8bio Reports Second Quarter 2025 Financial Results and Recent Business Highlights Delivered an oral presentation at ASCO 2025 Annual Meeting, demonstrating extended median progression-free survival (mPFS) in patients receiving multiple doses of INB-200, including a patient remaining progression-free for over four years.Received the Host Region USA East Abstract Award at ISCT 2025 for IN8bio’s DeltEx™ manufacturing platform.Presented preclinical data at ASGCT 2025 on INB-619, a novel gamma-delta T cell engager, and its ability to induce pan-gamma-delta T cell expansion and target CD19+ B c...

August 7, 2025 1 EN
 PRESS RELEASE
Free
INAB IN8BIO INC

IN8bio Recognizes Achievement of 4-Years in Remission for Patient Trea...

IN8bio Recognizes Achievement of 4-Years in Remission for Patient Treated with INB-200 in Glioblastoma Trial Patient with a grade 4, IDH-mutant, MGMT-methylated glioma remains alive and progression-free for four years after receiving treatment with the INB-200 gamma-delta T cell therapy in glioblastoma trial NEW YORK, June 09, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: INAB), a clinical-stage biopharmaceutical company developing innovative gamma-delta T cell therapies for cancer and autoimmune diseases, announced that Patient 009 in the Phase 1 trial of INB-200 for newly-diagnosed GBM has recen...

June 9, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch